- Home
- TEL vs MRNA Comparison
TEL vs MRNA Comparison
Compare TEL & MRNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | TEL | MRNA |
|---|---|---|
| Founded | 1941 | 2010 |
| Country | Ireland | United States |
| Employees | N/A | 4700 |
| Industry | Industrial Machinery/Components | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 62.6B | 61.6B |
| IPO Year | 2007 | 2018 |
Fundamental Metrics
Financial Performance| Metric | TEL | MRNA |
|---|---|---|
| Price | $200.89 | $153.46 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 15 | 12 |
| Target Price | ★ $257.27 | $34.27 |
| AVG Volume (30 Days) | 1.2M | ★ 27.7M |
| Earning Date | 04-22-2026 | 05-01-2026 |
| Dividend Yield | ★ 1.38% | N/A |
| EPS Growth | N/A | ★ 21.77 |
| EPS | ★ 7.98 | N/A |
| Revenue | $17,262,000,000.00 | ★ $19,263,000,000.00 |
| Revenue This Year | $14.07 | $9.36 |
| Revenue Next Year | $7.74 | $15.43 |
| P/E Ratio | $26.06 | ★ N/A |
| Revenue Growth | ★ 8.94 | 4.29 |
| 52 Week Low | $190.27 | $22.28 |
| 52 Week High | $252.56 | $176.66 |
Technical Indicators
Market Signals| Indicator | TEL | MRNA |
|---|---|---|
| Relative Strength Index (RSI) | 43.32 | 67.71 |
| Support Level | $200.55 | $41.01 |
| Resistance Level | $205.67 | $176.66 |
| Average True Range (ATR) | 5.21 | 15.90 |
| MACD | -0.58 | 3.23 |
| Stochastic Oscillator | 8.48 | 79.98 |
Price Performance
Historical ComparisonAbout TEL TE Connectivity Ltd. New Switzerland Registered Shares
TE Connectivity is the largest electrical connector supplier in the world, supplying interconnect and sensor solutions to the transportation, industrial, and communications markets. With operations in 150 countries and over 500,000 stock-keeping units, TE has a broad portfolio that forms the electrical architecture of its end customers' cutting-edge innovations.
About MRNA Moderna Inc.
Moderna is a commercial-stage biotech that was founded in 2010 and had its initial public offering in 2018. The firm's mRNA technology was rapidly validated with its covid vaccine, which was authorized in the United States in December 2020. Moderna had 25 mRNA development candidates in clinical studies as of March 2026. Programs span a wide range of therapeutic areas, including infectious disease, oncology, cardiovascular disease, and rare genetic diseases.